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ABSTRACT 
Objective: The purpose of this project was to describe pharmacy services in a patient-centered 
medical home to demonstrate pharmacists’ involvement in the evolving delivery of primary care. 
Design: This was a prospective, qualitative study.  Setting and Participants:  This project 
analyzed the work of eight pharmacists employed at a National Committee for Quality 
Assurance tier III patient-centered medical home associated with a large, academic medical 
center.  Outcome Measures: The primary outcome was to identify and quantify the types of 
services completed by pharmacists in a patient-centered medical home.  Secondary outcomes 
included determining the percentage of pharmacist recommendations accepted by providers and 
patients, the percentage of pharmacist interventions submitted for third-party reimbursement, and 
the average time spent per encounter.  Results: Eight pharmacists (representing 4.0 full-time 
equivalents) facilitated 581 encounters over 20 days.  Mean time spent per encounter was 20 
minutes (± 19).  The most common types of encounters were interdisciplinary visits (31.8%) 
and phone/secure portal communication (30.0%).  Of 918 pharmacist recommendations made to 
providers, 830 (90.4%) were accepted and implemented.  Of 412 pharmacist recommendations 
made to patients, 393 (95.4%) were verbally accepted.  Thirty-nine percent of encounters were 
eligible for direct payor billing.  Conclusion: Our data show that pharmacists working in a 
patient-centered medical home are effectively integrated within the evolving delivery of primary 
care.  Consistent inclusion of pharmacy services should be readily supported in future models of 
health care reform.  
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KEY POINTS 
Background: 
• Health system incentives and reimbursement have started to align with the delivery of team-
based care 
• Pharmacists inclusion in primary care delivery within value-based care models is less well-
defined 
• As the paradigm shifts from traditional fee-for-service to value-based care models, it is 
logical that pharmacists be consistently incorporated in these new payment models 
 
Findings: 
• Pharmacists involved in the delivery of primary care provide services that are consistently 
utilized to improve medication management  
• Pharmacists recommendations for traditional and evolving health care initiatives were 
accepted at high rates 
• Within the current payment model, pharmacists have limited opportunities for billing and 
sustainable reimbursement 
• Consistent inclusion of pharmacists to improve the quality of patient care and decrease health 
care costs should be supported in all future models of health care reform 
 
INTRODUCTION 
The percentage of adults with multiple chronic conditions1 who are prescribed two or more 
medications2 has steadily increased over time.  The aging population, high medical costs 
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associated with clinically complex patients, and the integration of information technology into 
health systems has led to an unsustainable rise in health care expenditures .3, 4 Furthermore, 
increased health care spending in the United States (U.S.) has not resulted in better patient 
outcomes with traditional health care models when compared to other nations.3 The transition 
from primary care services being rendered by an individual provider to comprehensive care 
provided by a team is foundational to high-performing primary care.5 Interdisciplinary teams 
allow individual practitioners with complementary skillsets and diverse clinical backgrounds to 
assist in the holistic care of patients.6-8 More recently, health system incentives and 
reimbursement have started to align with the delivery of team-based care.9  
 
The transition from traditional fee-for-service models to newer payment programs centered on 
value-based care is currently in progress.  The Centers for Medicare and Medicaid Services 
(CMS) declared that 50% of fee-for-service payments and 90% of traditional payments will be 
linked to value by 2018.9,10 Commercial payers have followed suit in instituting performance-
based reimbursement.4 The Medicare Access and CHIP Reauthorization Act (MACRA) of 2015 
proposed two quality payment program pathways for value-based care, including the Merit-
Based Incentive Payment System (MIPS) and alternative payment models (APMs).11 These 
value-based payments are not linked to a specific provider; instead, they incentivize health 
systems, clinical practices, and interdisciplinary teams to work toward better health and patient 
care at lower costs.12  As a result, many health systems are forming accountable care 
organizations (ACOs), establishing patient-centered medical homes (PCMH), and utilizing 
bundle payments and demonstration projects to capture market share.4, 9  While the 2011 Report 
to the U.S. Surgeon General noted that pharmacists are integrated into some primary care 
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practices as health care providers, the role of pharmacists within value-based care is less well-
defined.11, 13-14   
 
The Patient Protection and Affordable Care Act (PPACA) of 201015 expanded health care 
coverage, increasing the demand for primary care services. This demand cannot be fulfilled due 
to shortages within the current provider workforce.7, 16 Pharmacists are well-trained and uniquely 
positioned to help bridge the demand-capacity gap in primary care, yet their services are often 
underused and unrecognized.7, 14 Pharmacists have consistently demonstrated their ability to 
improve the quality of patient care, serve as a valuable resource for other health care providers 
and personnel, and empower patients to achieve their individualized goals.17 Direct patient care 
delivered by pharmacists has led to improved clinical outcomes and reduced costs for several 
medical conditions, including diabetes,18-19 hypertension,20-21 dyslipidemia22-23 and also increased 
patient satisfaction.24 Additionally, pharmacist-led anticoagulation clinics have demonstrated 
tremendous cost savings by reducing hospitalizations and emergency department visits when 
compared to usual care.25-26  
 
In the traditional fee-for-service model, pharmacists have limited opportunities for billing and 
sustainable reimbursement, as they are not currently recognized as health care providers by 
CMS; this has hindered the widespread implementation of pharmacists into physician practices.27 
However, recent changes to care delivery payment, such as capitation and shared savings 
contracts, in addition to the emphasis by PCMH credentialing bodies on medication management 
for populations28 has led to interest in incorporating pharmacists into the primary care setting.  
Currently, pharmacists working within an interdisciplinary team model have the ability to submit 
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current procedural terminology (CPT) codes for medication therapy management (MTM), 
contribute to chronic care management (CCM) or transitional care management (TCM), bill 
incident-to a provider, and bill annual wellness visits as means to generate revenue. 28 Despite 
the emergence of these billing techniques and pharmacist-specific CPT codes, reimbursement 
and relative value units (RVUs) continue to be more difficult to track for pharmacists when 
compared to other non-physician providers (e.g., physicians assistant, advanced nurse 
practitioner), thereby limiting pharmacist utilization in PCMH settings.  As the paradigm shifts 
from fee-for-service to value-based care, it is logical that pharmacists be consistently 
incorporated in these new payment models designed to improve patient outcomes and decrease 
overall costs.   
 
The successful implementation of pharmacists in a PCMH and other primary care settings has 
been described elsewhere,29-31 but there is limited literature describing how pharmacists should 
be incorporated into value-based models.  The purpose of this project was to provide an analysis 
of pharmacy services in a PCMH with the goal of demonstrating pharmacists’ involvement in the 
delivery of primary care.  The primary objective was to identify and quantify the types of 
services and interventions completed by pharmacists in a PCMH.  Secondary objectives included 
characterizing the patients impacted by pharmacists in this setting, and determining the 
percentage of pharmacist recommendations accepted by primary care providers, the percentage 
of pharmacist interventions submitted for third-party reimbursement, and the average time spent 
per encounter. 
 
METHODS 
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This study was conducted at five National Committee for Quality Assurance (NCQA) tier 3 
PCMH sites associated with a large, academic medical center.  Collectively, the interdisciplinary 
team includes 44 attending physicians, 108 medical residents, five pharmacists, three pharmacy 
residents, three nurse practitioners, 15 registered nurses, two social workers, and 47 medical 
assistants.  Over 59,000 patients receive primary care services within the five PCMH locations 
annually.  The health care payor mix includes 36.2% Medicare, 34.4% third-party insurance, 
26.6% Medicaid, and 2.3% uninsured.  The clinics utilize an electronic health record (EHR) that 
is integrated throughout the health system and contains clinical progress notes, medical condition 
lists, prescribed medications, laboratory values and imaging used to provide individualized 
patient care.  Pharmacists within this PCMH provide direct patient care, involving 
comprehensive medication management,32 and also lead an array of team-based services, such as 
interdisciplinary disease management clinics, population health and transitional care 
management.  Additionally, pharmacists serve as experiential educators to student pharmacists, 
medical students, and pharmacy, medical, and dental residents throughout the academic year.  
 
This was a prospective, descriptive study that included five pharmacists and three pharmacy 
residents employed within five PCMH locations.  Pharmacists used Qualtrics™ Survey Software 
to record their daily interventions electronically.  After each intervention made, pharmacists 
characterized the type of encounter; disease states and health-related topics addressed; number 
and type of pharmacist recommendations made to and accepted by providers and patients; billing 
techniques used (if applicable), and length of encounter (excluding pre- and post-encounter 
activities).  Patient demographics, including age, sex, race, insurance coverage, and number of 
home medications prior to the encounter were also recorded.  Pharmacists submitted their 
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interventions immediately after each encounter that occurred over the course of one calendar 
month (20 business days).  
 
Encounters were characterized as pharmacy visits (one-on-one office visits with a pharmacist); 
interdisciplinary visits (any office visit utilizing both a pharmacist and a physician and/or nurse 
practitioner); phone or secure portal communications; drug information requests (written and 
verbal inquiries from patients and/or healthcare personnel), or other.  Encounters were further 
classified as being scheduled, where pharmacy services were planned for a specific date and 
time, or unscheduled, where the delivery of pharmacy services occurred spontaneously 
throughout the course of a typical clinic day.  Pharmacists documented the specific disease states 
and/or health-related topics that required intervention during each encounter and also recorded if 
specific recommendations were accepted by providers and/or patients.  An accepted 
recommendation included any verbal or written agreement by the provider or patient to the 
proposed intervention prior to data submission.  An unaccepted recommendation included any 
verbal or written declination of the proposed intervention by the provider or patient prior to data 
submission.  Responses to recommendations that were not communicated to the pharmacist prior 
to data submission were classified as unknown.  
 
Billing techniques were categorized using CPT codes including incident-to (99211), provider 
billing (99213, 99214, 99215), transitional care management (99495, 99496) and insurance 
contracted comprehensive medication review (99605) codes.  Encounters that were not billed for 
reimbursement were classified as no charge.  This study was approved by the Institutional 
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Review Board at the Ohio State University (OSU).  Descriptive statistics were used for data 
analysis. 
 
RESULTS 
Five pharmacists and three pharmacy residents (representing 4.0 full-time equivalents) facilitated 
581 encounters over 20 clinic days between January 4, 2016 and February 1, 2016.  Mean time 
spent per encounter was 20 minutes (± 19).  Patient demographics were available for 543 
encounters.  Baseline characteristics of the patients are summarized in Table 1.  
 
The most common types of encounters were interdisciplinary visits (31.8%) and phone/secure 
portal communication (30.0%) (Figure 1).  One hundred sixty-eight (28.9%) encounters included 
pharmacy services that were scheduled and 413 (71.1%) encounters involved pharmacist 
interventions that occurred outside of pharmacist-scheduled office visits.  Approximately 45% of 
encounters involved face-to-face (in the office) patient interactions.  Collectively, pharmacists 
intervened on 616 disease states (Figure 2) and 262 health- and medication-related problems 
(Figure 3), most commonly addressing diabetes mellitus (24.8%), anticoagulation management 
(12.0%), or providing comprehensive medication reviews (8.1%).  Of 918 pharmacist 
recommendations made to providers, 830 (90.4%) were accepted and implemented at the time of 
the encounter (Table 2).  Of 412 pharmacist recommendations made to patients, 393 (95.4%) 
were verbally accepted (Table 3).  Two hundred twenty nine (39.4%) encounters were eligible 
for direct billing to a payor (Table 4).  
 
DISCUSSION 
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Traditional Clinical Services   
Our findings show the successful implementation of traditional pharmacy services, including 
diabetes and anticoagulation management, which have been evaluated outside of the PCMH 
model and shown to improve quality of care and reduce costs.14 Approximately 25% of our 
interventions involved diabetes management and education.  Studies have consistently 
demonstrated that pharmacist-driven diabetes programs improve clinical endpoints and 
significantly reduce direct medical costs.18-19, 33 Project IMPACT: Diabetes revealed that 
pharmaceutical care services not only led to clinically significant reductions in hemoglobin A1c 
(-0.8%), but positively influenced lipid parameters and health maintenance outcomes (including 
increases in the number of annual eye and foot examinations, influenza vaccinations, and 
smoking cessation).18  In the Asheville Project, the number of patients achieving optimal 
hemoglobin A1c (less than 7.0%) increased by 24.3% at the first follow-up, with additional 
increases of 27.2% and 18.2% noted at the second and third follow-ups, respectively.  As a result 
of pharmacist interventions, payors realized decreases in total direct costs and achieved a 
$4.00:$1.00 return-on-investment (ROI) at study conclusion. 19 These data combined with that of 
the current project support why pharmacists are at the forefront of diabetes care within this 
PCMH. 
 
One-eighth of our interventions involved anticoagulation management.  Chiquette et al 
demonstrated that a pharmacist-run anticoagulation clinic led to more international normalized 
ratios (INRs) within therapeutic range, reduced bleeding and thromboembolic events, and saved 
$162,058 per 100 patients annually in hospitalizations and emergency department (ED) visits.25 
Similarly, a more recent study comparing pharmacist-managed anticoagulation services to nurse-
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managed and usual care models found that pharmacist interventions yielded the lowest rates of 
hospital and ED visits, avoiding $141,277 and $10,183 in hospital stay and ED costs, 
respectively, during a one-year period.34  Furthermore, clinical pharmacists within a 
multispecialty group practice prevented 150 inpatient hospital admissions and saved $450,000 
annually by initiating an outpatient deep vein thrombosis protocol.26 Therefore, the pharmacist-
provided anticoagulation management services are corroborated by a strong, evidenced-based 
platform leading to incorporation within the PCMH model.  
 
Evolving Clinical Services  
Nearly one-fourth of our comprehensive medication reviews (CMRs) were billed using MTM 
CPT codes.  In 2006, pharmacists began to bill for the delivery of MTM services for Medicare 
beneficiaries using three pharmacist-specific CPT codes (99605, 99606, 99607).  Medicaid and 
select third-party payors have also recognized these codes, which has expanded pharmacist 
compensation in community and ambulatory settings.  CMS states that MTM services may be 
delivered by a pharmacist or other qualified provider.35 Our intervention data demonstrates that 
pharmacists are utilized to perform CMRs, identify medication-related problems, determine cost-
effective alternatives, solve medication access issues and create medication therapy plans.  After 
offering face-to-face MTM services to 900,000 members, an Ohio-based Medicaid program 
demonstrated a $1.35:$1.00 ROI in drug cost savings alone and a $4.00:$1.00 ROI in total 
savings, including avoided hospitalizations, ED visits, and other healthcare costs.36  
Unfortunately, not all payors recognize these CPT codes, limiting availability of this service to 
patients receiving care in a PCMH.  The inappropriate use of medication in the United States 
costs over $200 billion per year.37 Patients in our analysis were prescribed an average of 14 
12 
 
medications, reflecting the complexity of patients in this setting and the higher likelihood of 
medication discrepancies.  Of note, 107 of 917 recommendations were to discontinue an 
unnecessary medication; 97% of these recommendations were accepted by the patients’ primary 
care providers, decreasing pill burden and overall medication costs.   
 
In addition to diabetes, anticoagulation, and CMRs, pharmacists were consulted to assist with a 
wide variety of disease states and health-related initiatives, signifying the broad integration and 
supportive roles of pharmacists within a primary care environment.  While a large proportion of 
the encounters involved face-to-face interactions, many interactions also occurred through 
phone/EHR communications, which is consistent with the emerging use of health information 
technology.4 Pharmacists used telecommunications and e-health to assess current clinical status, 
reconcile medication lists, identify medication-related problems, and make clinical interventions.  
Telemedicine has been widely adopted by integrated health-systems, including the Veterans 
Health Administration and Kaiser Permanente, and is highly promoted in transforming the 
delivery of care; this modality of communication increases access to care, adds to convenience 
for patients and caregivers, and is central to concepts in newer payment models.38 Pharmacists in 
the current project facilitated TCM via phone, communicating with patients and/or caregivers 
within two business days of hospital discharge for medical reconciliation.  Recently, a pivotal 
study showed that payor participants in an insurer-initiated, pharmacist-led transitions of care 
program for high-risk patients experienced a 50% relative risk reduction of 30-day readmission 
and an absolute risk reduction of 11.1%.39 Furthermore, the program experienced a $2.00:$1.00 
ROI,  demonstrating that utilization of pharmacists for TCM improves the quality of hospital-to-
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home transitions through identification of medication discrepancies40, but also positively impacts 
reimbursement for post-discharge office visits28 and reduces 30-day readmissions.39  
 
Although chronic care management (CCM) reflected less than 1% of billing techniques used, the 
identification of CCM patients in the EHR was not retrievable data at the time of this study. It is 
possible that pharmacist-completed phone and EHR communications may have contributed to 
use of CCM billing by the PCMH.  Despite this, CCM is another viable opportunity for 
pharmacists to maximize reimbursement through collaboration with other health care personnel 
to optimize therapeutic outcomes, while tracking time spent on clinical activities which is 
supported by recently implemented billing processes.  Additionally, our results demonstrate the 
development and incorporation of newer services related to transforming health care delivery.  
Finally, not captured within our data is pharmacist-driven population health management that 
was ongoing during this observation, though the impact of these initiatives has been previously 
reported.41-43 Advanced population health management initiatives are being further explored by 
pharmacists, providers, and payors as they have contributed to the success of tightly integrated 
pharmacy models in health systems4 and may be linked to improved patient outcomes or value-
based support. 
 
Clinical Implications  
Mean time spent facilitating each encounter was 20 minutes, excluding pre- and post- encounter 
activities.  The CAPTION study showed pharmacists spent 4.99 hours/patient in pre-visit, post-
visit, and intra-service work managing hypertension for 390 patients over 2811 encounters 
within nine months, yielding a 43% improvement in blood pressure goals achieved from 
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baseline.  This study provided insight as to how policymakers and health administrators can 
understand and measure pharmacists’ workload as alternative payment models are being 
designed and implemented.21  
 
One-third of encounters were directly facilitated by an interdisciplinary team, with the vast 
majority of interventions involving shared-decision making between the pharmacist, provider, 
and/or patient prior to acceptance.  Seventy-one percent of pharmacists’ encounters occurred 
unpremeditated throughout the routine course of patient care activities, indicating that 
pharmacists were easily accessible and readily available to render services in this setting.  The 
acceptance rate of pharmacist recommendations to providers was high, which is consistent with 
previous literature.14, 21, 29 Pharmacists’ recommendations to patients were verbally accepted at 
similarly high rates, suggesting the need for pharmacists’ collaboration in their care.  These 
results illustrate how pharmacists working in teams can be successfully utilized in the delivery of 
patient care.  Additionally, these results serve as an example of the integrated services of 
pharmacists in an established PCMH model of care.  The changing payment structure for clinics 
necessitates that pharmacists position themselves to be incorporated into multiple aspects of 
patient care to collaborate on team-based initiatives, patient care access, and improve patient 
outcomes.6, 8  
 
LIMITATIONS 
Limitations of this study include the potential under-reporting of interventions by pharmacists; to 
minimize this, pharmacists were asked to complete data submission immediately after each 
encounter.  A training session was held for participating pharmacists and the data collection form 
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was piloted prior to implementation to reduce inter-participant variability.  Limitations in 
quantifying the pharmacists’ activities were related to development of the data collection 
instrument.  The focus of this tool was on capturing patient encounter data and subsequent 
interventions, thereby omitting other valuable supportive activities completed by pharmacists in 
this PCMH (e.g. population management).  Tracking of chronic care management billing was 
also not captured, as this was a newly developed interdisciplinary service for our clinic at the 
time of data collection.  Finally, in retrospect our data collection tool did not capture time spent 
working behind the scenes to improve the quality of medication use, including activities such as 
daily patient chart reviews to assess for medication therapy outcomes, overlooked adverse 
effects, and potentially significant drug interactions.  These activities have been identified as key 
vital pharmacists’ tasks helping providers provide interdisciplinary quality care.38  
 
Future Directions 
This study characterizes the daily activities of pharmacists in a PCMH; however two-thirds of 
encounters did not result in direct billing or reimbursement.  With health care payment reform 
and recognized provider status of pharmacists, opportunities to bill would increase, allowing 
practices to justify the addition of a pharmacist to the practice.  As the delivery of health care is 
transforming, the shift toward value-based payment may help to remove the cost barrier to hiring 
pharmacists that cannot bill directly under the current fee-for-service model.  Pharmacists’ 
medication expertise provides a very highly trained level of team care support for complex 
patients that cannot be achieved by other clinical staff; yet, pharmacists also participate in 
multiple indirect patient care activities that are fundamental to a successful PCMH.  Future 
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descriptions of pharmacists’ involvement in a PCMH should include time dedicated to these 
activities to establish adequate staffing in team-based models.    
 
CONCLUSION 
In summary, pharmacists within this PCMH were easily accessible and readily available to 
participate in a wide variety of traditional and evolving clinical services. Pharmacists’ 
recommendations were accepted at high rates by providers and patients, demonstrating that 
pharmacists working in a PCMH model can effectively lead and support the value-based model 
of care. Pharmacist’s recognition as essential providers advancing change in these newer models 
of care are vital to successful implementation in value based systems. The consistent inclusion of 
pharmacists to improve the quality of patient care, enhance medication safety, and decrease 
health care costs should be supported in all future models of health care reform.   
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Encounter Type Percentage 
Interdisciplinary visits (N=185) 31.8 
Phone/secure portal communication (N=174) 30.0 
Drug information requests (N=133) 22.9 
Pharmacy visits (N=78) 13.4 
Other (N=11) 1.9 
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Figure 2. Interventions by Disease State (N=616)
*Other included attention deficit hyperactive disorder, anemia, autism, celiac’s disease, cognitive 
impairment, constipation, cough/cold, dermatology, genitourinary, gout, heart failure, insomnia, 
migraine, oncology, osteoporosis, obesity, pre-diabetes, renal/hepatic disease
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Figure 3. Interventions by Health-Related Issue (N=262)
**Other included medication adherence, chronic care management, gene-testing, home 
visits, monitoring, nutrition, urine toxicology screening
Table 1: Baseline Characteristics (n = 543) 
Mean age (years) ± SD  58 ± 17 
Male, n (%) 245 (45) 
Race, n (%)  
Caucasian 358 (66) 
African-American 139 (26) 
 Othera 46 (8) 
Insurance, n (%)  
Medicare 256 (47) 
Medicaid  123 (23) 
Private insurance  137 (25) 
Self-pay or unknown 26 (5) 
Mean number of home medications  ± SD 14 ± 7 
aOther included Indian, Nepali, Ethiopian, Mediterranean, and unknown 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2. Recommendations Made to Physician (N=918) 
 
aOther included device teaching, dosage form recommendations, EHR updates, medication cost assistance (prior 
authorization, insurance, drug manufacturer acquisition programs), medication refills, home monitoring, patient 
education, provider education, assisting with prescriber drug entry into EHR, drug information, referral to 
PCP/specialist or not otherwise specified. 
  
Recommendation, n (%) Made Accepted Not Accepted Unknown 
New drug 136 128 (94.1) 1 (0.7) 7 (5.2) 
Alternate drug 110 96 (87.3) 5 (4.5) 9 (8.2) 
Unecessary drug 107 104 (97.2) 2 (1.9) 1 (0.9) 
Dose increase 104 101 (97.1) 3 (2.9) 0  
Dose decrease 55 51 (92.7) 3 (5.5) 1 (1.8) 
No dose change 41 41 (100) 0  0 
Drug interaction/adverse event 42 40 (95.2) 0 2 (4.8) 
Monitoring parameters 151 134 (88.7) 3 (2.0) 14 (9.3) 
Medication adherence 54 51( 94.4) 0 3 (5.6) 
Othera 118 84 (71.2) 5 (4.2) 29 (24.6) 
Total 918 830 (90.4) 22 (2.4) 66 (7.2) 
Table 3. Recommendations Made to Patient  (N=412) 
 
Recommendation, n (%) Made Accepted Not Accepted Unknown 
Immunizationsa 27 23 (85.2) 4 (14.8) 0 
Lifestyle modificationsb 117 111 (94.8) 3 (2.6) 3 (2.6) 
Medication adherenceb 169 165 (97.6) 2 (1.2) 2 (1.2) 
OTC recommendationsb 25 25 (100.0) 0 0 
Otherc 74 69 (93.2) 3 (4.1) 2 (2.7) 
Total 412 393 (95.4) 12 (2.9) 7 (1.7) 
aAdministered prior to patient departure from clinic  
bRecommendation was documented as accepted if patient verbalized agreement; however, implementation of these 
recommendations were not tracked after patient departure from clinic 
cOther included device teaching, drug recommendations (initiating new medications), education (adverse 
effects/hypoglycemia/nutrition), medication cost assistance (insurance discrepancies/deductibles), medication 
review (home health nurse), self-monitoring, referral (PCP/specialist/education course). 
  
 Table 4. Billing Techniques Used For Patient Encounters (N=581) 
Billing Codes Encounters (%) 
No Charge 352 (60.6) 
Billed by Provider (99213, 99214, 99215)a 129 (22.2) 
Transitional Care Management (99495, 99496) 45 (7.8) 
Incident to (99211) 32 (5.5) 
Insurance-contracted comprehensive medication review (99605)b  19 (2.9) 
Otherc 4 (0.7) 
a During interdisciplinary/combined visits  
bMedication therapy management code 
cOther included Chronic Care Management billing codes. 
